Last reviewed · How we verify
NCT05761743
Glycemic Control, Type II Diabetes, Parathyroidectomy
trial testing Urine and Blood Test in Primary Hyperparathyroidism in 80 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2025
Quick facts
| Lead sponsor | The Cleveland Clinic |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 27 February 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 1 February 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Urine and Blood Test
Conditions studied
- Primary Hyperparathyroidism — all drugs for Primary Hyperparathyroidism →
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
The Cleveland Clinic
Who can join
18 and older, any sex, with Primary Hyperparathyroidism or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess glycemic control after parathyroidectomy in patients with primary hyperparathyroidism and concomitant type 2 diabetes mellitus.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05761743
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Hyperparathyroidism
Currently open trials in the same condition.
- NCT07444723 — Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors · Phase 2, PHASE3 · recruiting
- NCT06859580 — Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism · Phase 4 · recruiting
- NCT05997810 — Parathyroid Tumor Clonal Status · recruiting
- NCT07138820 — 18F-choline Positron-emission-tomography - Computed-tomography Compared to Conventional Imaging for Localizing Diseased · NA · recruiting
- NCT06523582 — Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients · recruiting
Other The Cleveland Clinic trials
Trials by the same sponsor.
- NCT07218198 — Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension · NA · not yet recruiting
- NCT07442747 — Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS · NA · not yet recruiting
- NCT07471464 — Centered Surgery - Preoperative Counseling and Patient Satisfaction · recruiting
- NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
- NCT07363343 — Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05761743 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Cleveland Clinic
- Last refreshed: 6 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05761743.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing